" class="no-js "lang="en-US"> Ping An - Medtech Alert
Friday, April 03, 2026

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Ping An | Pharmtech Focus

Ping An

About Ping An

Ping An

This is the official Company Page of Ping An Insurance (Group) Company of China, Ltd. (HKEx: 2318; SSE: 601318; ADR: PNGAY).

Ping An strives to become a world leading technology-powered financial services group. We believe the way people receive financial services and healthcare in the future will be through intelligent ecosystems enabled by technology.

With over 214 million retail customers and nearly 579 million Internet users, Ping An is one of the largest financial services companies in the world.

Technology has enabled us to bring changes to the landscape of retail finance and healthcare in China. Supported by the Group’s strong core financials, our continued investment in fintech and healthtech resulted in increasing revenue contributions from our tech units as well as several unicorns.

In 2021, Ping An ranked 6th in the Forbes Global 2000 list and ranked 21st in the Fortune Global 500 list in 2020.

Follow us for latest news, events and job opportunities.

Related Story

Artificial Intelligence

 Ping An Makes Breakthrough in Artificial Intelligence-Driven Drug Research | Pharmtech Focus

Ping An Makes Breakthrough in Artificial Intelligence-Driven Drug Research

June 21 2021

Research by Ping An Healthcare Technology Research Institute and Tsinghua University has led to a […]